1. ¹Department of Radiation Oncology, UC Davis Cancer Center, University of California, Davis, Sacramento, California, USA
2. ²Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA

Correspondence: S Vijayakumar, Department of Radiation Oncology, UC Davis Cancer Center, University of California, Davis, 4501 X Street, G126, Sacramento, CA 95817, USA. E-mail: william.hall@ucdmc.ucdavis.edu

Received 9 June 2004; Revised 20 September 2004; Accepted 29 September 2004; Published online 8 February 2005.

Abstract

The management of localized prostate cancer is based on stage, grade, PSA, and subjective assessment of comorbidity and life expectancy. Over the last 15 y, stage migration and the improved use of Gleason sum, PSA and TNM staging have led to many treatment options for patients with newly diagnosed localized prostate cancer. At the same time, advances in treatment techniques have helped decrease the long-term complications of surgery and radiotherapy. However, the importance of age and comorbidity, in survival outcomes and treatment decision-making has been largely overlooked. Currently, stage, grade, and PSA are the only quantifiable variables consistently used in research and treatment decision-making. Comorbidity and life expectancy have remained largely subjective variables. Increasing longevity and a rapidly aging population have made age and comorbidity increasingly important factors in clinical research and treatment decision-making. This article reviews the importance of age and comorbidity on treatment decisions and survival outcomes in prostate cancer, as well as their use as objectively quantifiable variables. Examples from the general oncology literature are given. The overview also examines validated comorbidity indices and advocates the use of the Charlson Comorbidity Index (CCI) in research outcomes and treatment decision-making in prostate cancer. Several clinical vignettes are provided to demonstrate the potential clinical utility of the CCI as applied to prostate cancer.